Epstein Files Full PDF

CLICK HERE
Technopedia Center
PMB University Brochure
Faculty of Engineering and Computer Science
S1 Informatics S1 Information Systems S1 Information Technology S1 Computer Engineering S1 Electrical Engineering S1 Civil Engineering

faculty of Economics and Business
S1 Management S1 Accountancy

Faculty of Letters and Educational Sciences
S1 English literature S1 English language education S1 Mathematics education S1 Sports Education
teknopedia

  • Registerasi
  • Brosur UTI
  • Kip Scholarship Information
  • Performance
Flag Counter
  1. World Encyclopedia
  2. Volume of distribution - Wikipedia
Volume of distribution - Wikipedia
From Wikipedia, the free encyclopedia
(Redirected from Initial volume of distribution)
Theoretical drug measure in pharmacology
Further information: Distribution (pharmacology)

In pharmacology, the volume of distribution ( V D {\displaystyle V_{D}} {\displaystyle V_{D}}, also known as apparent volume of distribution or volume of dilution[1]) is the theoretical volume that would be necessary to contain the total amount of an administered drug at the same concentration that it is observed in the blood plasma.[2]

Roughly speaking, the V D {\displaystyle V_{D}} {\displaystyle V_{D}}, as a property of a drug, measures the degree to which it is distributed in body tissue rather than the blood plasma. Drug properties which cause high V D {\displaystyle V_{D}} {\displaystyle V_{D}} include high lipid solubility (non-polarity), low rates of ionization, or low plasma protein binding capabilities. Disease states which increase V D {\displaystyle V_{D}} {\displaystyle V_{D}} include kidney failure (due to fluid retention) and liver failure (due to altered body fluid and plasma protein binding). Conversely, dehydration may decrease V D {\displaystyle V_{D}} {\displaystyle V_{D}}.

The initial volume of distribution describes blood concentrations prior to attaining the apparent volume of distribution and uses the same formula.

Motivation and equation

[edit]

Suppose one administers an amount of drug D {\displaystyle D} {\displaystyle D} intravascularly, then measures the drug concentration in blood C 0 {\displaystyle C_{0}} {\displaystyle C_{0}} (assuming enough time has elapsed for the drug to distribute, but not enough time for elimination). The volume of distribution is the quotient:

V D = D C 0 {\displaystyle V_{D}={\frac {D}{C_{0}}}} {\displaystyle V_{D}={\frac {D}{C_{0}}}}

If the drug remains entirely intravascularly, V D {\displaystyle V_{D}} {\displaystyle V_{D}} will be identical to the blood volume V b l o o d {\displaystyle V_{blood}} {\displaystyle V_{blood}}. However, if a drug diffuses out of the intravascular space into the tissues or interstitium, the measured concentration will be lower-than-expected compared to a hypothetical intravascular-only drug. Therefore, V D > V b l o o d {\displaystyle V_{D}>V_{blood}} {\displaystyle V_{D}>V_{blood}}, with a higher V D {\displaystyle V_{D}} {\displaystyle V_{D}} value corresponding to a greater tendency for the drug to exit the intravascular space.

One clinical utility is that the dose required D {\displaystyle D} {\displaystyle D} to achieve a target plasma concentration C 0 {\displaystyle C_{0}} {\displaystyle C_{0}} can be determined if the V D {\displaystyle V_{D}} {\displaystyle V_{D}} for that drug is known.

The V D {\displaystyle V_{D}} {\displaystyle V_{D}} is not a physiological value; it is more a reflection of how a drug will distribute throughout the body depending on several physicochemical properties such as solubility, charge, size, etc.

The unit for V D {\displaystyle V_{D}} {\displaystyle V_{D}} may be reported extensively in litres (for a patient of given weight), or intensively as litres-per-kilogram.

The V D {\displaystyle V_{D}} {\displaystyle V_{D}} may also be used to determine how readily a drug will displace into the body tissue compartments relative to the blood:

V D = V P + V T ( f u P f u T ) {\displaystyle {V_{D}}={V_{P}}+{V_{T}}\left({\frac {f_{u_{P}}}{f_{u_{T}}}}\right)} {\displaystyle {V_{D}}={V_{P}}+{V_{T}}\left({\frac {f_{u_{P}}}{f_{u_{T}}}}\right)}

Where:

  • V P {\displaystyle V_{P}} {\displaystyle V_{P}}: plasma volume
  • V T {\displaystyle V_{T}} {\displaystyle V_{T}}: apparent tissue volume
  • f u P {\displaystyle f_{u_{P}}} {\displaystyle f_{u_{P}}}: fraction unbound in plasma
  • f u T {\displaystyle f_{u_{T}}} {\displaystyle f_{u_{T}}}: fraction unbound in tissue

Examples

[edit]
Main article: Table of volume of distribution for drugs
See also: Pharmacokinetics § Metrics

For example, chloroquine has much greater affinity for body fat than blood, resulting in a V D ≈ 250 L / k g {\displaystyle V_{D}\approx 250L/kg} {\displaystyle V_{D}\approx 250L/kg} [3] compared to V b l o o d ≈ 0.08 L / k g {\displaystyle V_{blood}\approx 0.08L/kg} {\displaystyle V_{blood}\approx 0.08L/kg}.[4]

Example V D {\displaystyle V_{D}} {\displaystyle V_{D}} values for a 70 kg man,[5] with approximate blood volume 5-6L.
Drug V D {\displaystyle V_{D}} {\displaystyle V_{D}} Comments
Warfarin 8 L Reflects a high degree of plasma protein binding, which sequesters the drug in the intravascular space.
Theophylline, Ethanol 30 L Represents distribution in total body water.
Chloroquine 15000 L Shows highly lipophilic molecules which sequester into total body fat.
NXY-059 8 L Highly charged hydrophilic molecule.

References

[edit]
  1. ^ Ward RM, Kern SE, Lugo RA (2012). "Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics". Avery's Diseases of the Newborn. Elsevier. pp. 417–428. doi:10.1016/b978-1-4377-0134-0.10034-4. ISBN 978-1-4377-0134-0.
  2. ^ "Volume of distribution". sepia.unil.ch. Retrieved 19 April 2018.
  3. ^ Wetsteyn JC, De Vries PJ, Oosterhuis B, Van Boxtel CJ (June 1995). "The pharmacokinetics of three multiple dose regimens of chloroquine: implications for malaria chemoprophylaxis". British Journal of Clinical Pharmacology. 39 (6): 696–699. doi:10.1111/j.1365-2125.1995.tb05731.x. PMC 1365086. PMID 7654492.
  4. ^ Alberts B (2005). "Leukocyte functions and percentage breakdown". Molecular Biology of the Cell. Retrieved 2007-04-14 – via NCBI Bookshelf.
  5. ^ Swain C. "Distribution and plasma protein binding". Cambridge MedChem Consulting. Retrieved 2020-04-02.

External links

[edit]
  • Tutorial on volume of distribution
  • Overview at icp.org.nz Archived 2008-10-14 at the Wayback Machine
  • Overview at cornell.edu
  • Overview at stanford.edu
  • Overview at boomer.org
  • v
  • t
  • e
Pharmacology
Ligand (biochemistry)
Excitatory
  • Agonist
  • Endogenous agonist
  • Irreversible agonist
  • Partial agonist
  • Superagonist
  • Physiological agonist
Inhibitory
  • Antagonist
  • Competitive antagonist
  • Irreversible antagonist
  • Physiological antagonist
  • Inverse agonist
  • Enzyme inhibitor
  • Drug
  • Neurotransmitter
  • Agonist-antagonist
  • Pharmacophore
Pharmacodynamics
Activity at receptor
  • Mechanism of action
  • Mode of action
  • Binding
  • Receptor (biochemistry)
  • Desensitization (medicine)
  • Other effects of ligand
    • Selectivity (Binding, Functional)
    • Pleiotropy (drugs)
    • Non-specific effect of vaccines
    • Adverse effect
    • Toxicity (Neurotoxicity)
    Analysis
    • Dose–response relationship
    • Hill equation (biochemistry)
    • Schild plot
    • Del Castillo Katz model
    • Cheng-Prussoff Equation
    • Methods (Organ bath, Ligand binding assay, Patch clamp)
    Metrics
    • Efficacy
    • Intrinsic activity
    • Potency (EC50, IC50, ED50, LD50, TD50)
    • Therapeutic index
    • Affinity
    Pharmacokinetics
    Metrics
    • Loading dose
    • Volume of distribution (Initial)
    • Rate of infusion
    • Onset of action
    • Biological half-life
    • Plasma protein binding
    • Bioavailability
    LADME
    • (L)ADME: (Liberation)
    • Absorption
    • Distribution
    • Metabolism
    • Excretion (Clearance)
    • Compartment
    • Bioequivalence
    Related
    fields
    Neuroscience and psychology
  • Neuropsychopharmacology
  • Neuropharmacology
  • Psychopharmacology
  • Electrophysiology
  • Medicine
    • Clinical pharmacology
    • Pharmacy
    • Medicinal chemistry
    • Pharmacoepidemiology
    Biochemistry and genetics
    • Pharmacoinformatics
    • Pharmacogenetics
    • Pharmacogenomics
    Toxicology
    • Pharmacotoxicology
    • Neurotoxicology
    Drug discovery
    • Classical pharmacology
    • Reverse pharmacology
    • Photopharmacology
    • Immunopharmacology
    • Cell biology
    • Physiology
    Other
  • Coinduction (anesthetics)
  • Combination therapy
  • Functional analog (chemistry)
  • Polypharmacology
  • Chemotherapy
  • Lists of drugs
  • WHO list of essential medicines
  • Tolerance and resistance
    • Drug tolerance
    • Tachyphylaxis
    • Drug resistance
    • Antibiotic resistance
    • Multiple drug resistance
    Antimicrobial pharmacology
    • Antimicrobial pharmacodynamics
    • Minimum inhibitory concentration
    • Bacteriostatic
    • Minimum bactericidal concentration
    • Bactericide
    Retrieved from "https://teknopedia.ac.id/w/index.php?title=Volume_of_distribution&oldid=1330961623"
    Category:
    • Pharmacokinetics
    Hidden categories:
    • Articles with short description
    • Short description is different from Wikidata
    • Webarchive template wayback links

    • indonesia
    • Polski
    • العربية
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • مصرى
    • Nederlands
    • 日本語
    • Português
    • Sinugboanong Binisaya
    • Svenska
    • Українська
    • Tiếng Việt
    • Winaray
    • 中文
    • Русский
    Sunting pranala
    url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url
    Pusat Layanan

    UNIVERSITAS TEKNOKRAT INDONESIA | ASEAN's Best Private University
    Jl. ZA. Pagar Alam No.9 -11, Labuhan Ratu, Kec. Kedaton, Kota Bandar Lampung, Lampung 35132
    Phone: (0721) 702022
    Email: pmb@teknokrat.ac.id